GILEAD SCIENCES, INC. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
GILEAD SCIENCES, INC. (GILD) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of $2.06 billion for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-02-24
- GILEAD SCIENCES, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was $2.06B, a 1318.62% increase from fiscal 2024.
- GILEAD SCIENCES, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was $145.00M, a 89.93% decline from fiscal 2023.
- GILEAD SCIENCES, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was $1.44B.
- GILEAD SCIENCES, INC. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2013 was $1.47B, a 16.51% increase from fiscal 2012.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | $2.06B 10-K · filed 2026-02-24 |
| 2024-12-31 | $145.00M 10-K · filed 2026-02-24 |
| 2023-12-31 | $1.44B 10-K · filed 2026-02-24 |
| 2013-12-31 | $1.47B 10-K · filed 2014-02-25 |
| 2012-12-31 | $1.26B 10-K · filed 2014-02-25 |
| 2011-12-31 | $1.28B 10-K · filed 2014-02-25 |
| 2010-12-31 | $1.37B 10-K · filed 2013-02-27 |
| 2009-12-31 | $1.23B 10-K · filed 2012-02-23 |
| 2008-12-31 | $935.44M 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |